Q-omics provides the consensus-scored C4orf3 profile across patient tissues and cancer cell-line models. C4orf3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C4orf3 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, C4orf3 RNA expression shows 19,059 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, KICH, and ACC as cancer lineages where C4orf3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C4orf3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C4orf3 survival associations across molecular data types. C4orf3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C4orf3 RNA expression–survival associations across cancer types. High C4orf3 expression shows unfavorable associations in HNSC, KICH and COAD, but favorable associations in KIRC, MESO and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C4orf3 RNA expression.
This table summarizes C4orf3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for C4orf3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C4orf3 shows lower tumor expression in KICH, BLCA, LUAD, KIRP, BRCA and THCA. The KICH box plot shows higher C4orf3 RNA expression in normal versus tumor tissue (log2 FC = −1.297, t-test p < 0.001).
This table shows molecular features associated with C4orf3 in patient tissues and cancer cell lines. In patient samples, C4orf3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, C4orf3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
